Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psychiatric side effects of VEGF receptor tyrosine kinase inhibitors
NL-OMON30546Withdrawn
- Sponsor
- Erasmus MC
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Single-arm trial of sorafenib in cancer, sponsored by Erasmus MC. Primary endpoint: Psychiatric side effects. Planned start Jun 2007; status: withdrawn.
02
Drugs
sorafenib
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON30546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30546.